STERIS plc (NYSE:STE) Shares Acquired by Central Valley Advisors LLC

Central Valley Advisors LLC boosted its stake in STERIS plc (NYSE:STE) by 10.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,182 shares of the medical equipment provider’s stock after acquiring an additional 609 shares during the quarter. Central Valley Advisors LLC’s holdings in STERIS were worth $1,271,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Acadian Asset Management LLC purchased a new stake in shares of STERIS during the second quarter worth about $227,000. Brown Brothers Harriman & Co. boosted its holdings in STERIS by 154.7% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 191 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 116 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in STERIS by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 840,194 shares of the medical equipment provider’s stock worth $184,439,000 after buying an additional 95,412 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in shares of STERIS by 11.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 6,408 shares of the medical equipment provider’s stock valued at $1,407,000 after acquiring an additional 666 shares during the last quarter. Finally, Waterloo Capital L.P. lifted its position in shares of STERIS by 3.2% in the second quarter. Waterloo Capital L.P. now owns 1,916 shares of the medical equipment provider’s stock valued at $421,000 after acquiring an additional 59 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Stock Up 1.6 %

Shares of STE opened at $209.96 on Friday. The stock has a fifty day simple moving average of $212.23 and a two-hundred day simple moving average of $224.79. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $20.72 billion, a PE ratio of 47.94 and a beta of 0.84. STERIS plc has a 52-week low of $197.82 and a 52-week high of $248.24.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.02. The firm had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. STERIS’s revenue was up 7.3% compared to the same quarter last year. During the same period last year, the business earned $2.03 earnings per share. As a group, equities analysts forecast that STERIS plc will post 9.1 EPS for the current year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 19th. Investors of record on Tuesday, November 19th were given a $0.57 dividend. The ex-dividend date of this dividend was Tuesday, November 19th. This represents a $2.28 annualized dividend and a yield of 1.09%. STERIS’s payout ratio is 52.05%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on STE shares. Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 target price on shares of STERIS in a report on Monday, November 18th. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Stephens reaffirmed an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research note on Thursday, November 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, STERIS presently has a consensus rating of “Moderate Buy” and an average target price of $262.50.

Insider Buying and Selling

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the transaction, the senior vice president now owns 11,372 shares of the company’s stock, valued at $2,471,363.04. This trade represents a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.14% of the stock is currently owned by company insiders.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.